3 unknown, 2 recruiting, 1 terminated. 6 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 6 | Unknown 3, Recruiting 2, Terminated 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT Abatacept - Hematologic Malignancy | Early Phase 1 | Recruiting | Duke University | 10 | 2025-11-12 | 2026-11-06 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies engineered red blood cell - Cancer, Solid Tumor | Early Phase 1 | Unknown | Westlake Therapeutics | 30 | 2023-01-16 | 2024-07-24 |
| A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001) isatuximab 10 mg/kg - Platelet Refractoriness, Hematologic Malignancy | Early Phase 1 | Terminated | Firas El Chaer, MD | 3 | 2022-11-29 | 2024-07-31 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CD123-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2019-11-12 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CLL1-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2021-05-19 |
Hematologic Neoplasms (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Leukemia (2) · Myeloproliferative Disorders (2) · Anemia, Aplastic (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms by Site (6) · Neoplasms (5) · Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3) · Leukemia, Myeloid (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Anemia (1) · Blood Protein Disorders (1) · Bone Marrow Failure Disorders (1) · Cardiovascular Diseases (1)
Abatacept (1) · daratumumab (1) · isatuximab (1)
iCell Gene Therapeutics (2) · Duke University (1) · Firas El Chaer, MD (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Westlake Therapeutics (1)
China (3) · United States (3)
Fang Liu, MD, PhD (2) · Hongyu Zhang, MD, PhD (2) · Christian B Gocke, MD, PhD (1) · Firas El Chaer, MD (1) · Sanghee Hong, MD (1)